肠道菌群
药理学
中医药
佐剂
癌症免疫疗法
免疫疗法
免疫
化学
癌症
脂肪酸代谢
临床疗效
代谢途径
医学
癌症研究
生物
新陈代谢
结直肠癌
脂肪酸
能量代谢
计算生物学
β氧化
机制(生物学)
单克隆抗体
细胞代谢
生物化学
代谢调节
作者
Meiling Zheng,Yufeng Meng,Jingli Feng,Hong-ge Liang,Xinlin Mu,Cui-Ling Feng
出处
期刊:Phytomedicine
[Elsevier BV]
日期:2025-11-19
卷期号:149: 157559-157559
标识
DOI:10.1016/j.phymed.2025.157559
摘要
SLBZS, as a traditional Chinese medicinal formulation, enhances the efficacy of PD-1 mAb through a unique dual-regulatory mechanism. It concurrently remodels the gut microbiota structure and optimizes the metabolic microenvironment, with these synergistic actions collectively amplifying anti-tumor immunity while reducing irAEs. This dual-mode efficacy distinguishes SLBZS from conventional microbial modulators that solely target microbiota without metabolic coordination. Our study provides the first experimental validation of SLBZS as a clinically valuable adjuvant of Chinese medicinal origin for NSCLC immunotherapy. Furthermore, we pioneer a novel research paradigm integrating traditional Chinese medical theory with the "microbiota-metabolism-immune network" axis, thereby offering innovative therapeutic strategies for refining cancer immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI